MYOHIGH SIGNALFINANCIAL10-K

MYO shows severe financial deterioration with massive revenue spike that appears anomalous alongside dramatically worsening losses, cash burn, and equity destruction.

The 40,000%+ revenue increase to $1B appears to be a data error or extraordinary one-time event, as it's inconsistent with the company's historical scale and worsening operational metrics. The authentic concern is the tripling of cash burn, halving of stockholders' equity, and 151% increase in net losses, indicating severe financial distress for what appears to be a medical device company.

Comparing 2026-03-09 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

While revenue shows an implausible 40,000% jump to $1B, all other metrics indicate severe deterioration - net losses increased 152% to -$15.6M, operating cash flow worsened 341% to -$14.5M, and stockholders' equity collapsed 54% to $11.4M. Cash reserves declined 42% to $14.1M while total liabilities surged 55% to $27.2M, painting a picture of a company burning through capital at an unsustainable rate despite the reported revenue anomaly. The financial profile suggests significant distress and potential going concern issues regardless of the questionable revenue figure.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+40814.8%
$2.4M$1.0B

Strong top-line growth of 40814.8% — accelerating demand or successful expansion into new markets.

Operating Cash Flow
Cash Flow
-341.1%
-$3.3M-$14.5M

Operating cash flow fell 341.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-151.9%
-$6.2M-$15.6M

Net income declined 151.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-132%
-$6.2M-$14.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Liabilities
Balance Sheet
+55.4%
$17.5M$27.2M

Liabilities grew 55.4% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-53.9%
$24.7M$11.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+45.5%
$4.8M$6.9M

R&D investment increased 45.5% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-42%
$24.4M$14.1M

Cash declined 42% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
+28.1%
$1.4M$1.7M

Capex increased 28.1% — ongoing investment in capacity or infrastructure for future growth.

Current Liabilities
Balance Sheet
-18%
$10.2M$8.3M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-10
ADDED
At March 2, 2026, the registrant had 38,511,715 shares o f common stock, par value $0.0001 per share, outstanding.
We may not be able to obtain third-party payer reimbursement, including reimbursement by Medicare, for our products.
Changes made by direct to consumer advertising platforms (such as social media) in how they reach prospective patients could adversely impact our lead generation efforts, resulting in higher advertising cost per addition to our patient pipeline and have an adverse effect on revenues.
We may not have sufficient funds to meet our future capital requirements.
The terms of our Loan and Security Agreement with Avenue Capital Management II, L.P.
+7 more — sign up free →
REMOVED
At March 1, 2025, the registrant had 34,381,125 sha res of common stock, par value $0.0001 per share, outstanding.
We may not be able to obtain adequate levels of third-party payer reimbursement, including reimbursement by Medicare, for our products.
We currently rely, and in the future will rely, on sales of our MyoPro products for our revenue, and we may not be able to achieve or maintain market acceptance.
Food and Drug Administration, or ( FDA ), listings, select appropriate patients and provide adequate follow-on care.
We are subject to extensive governmental regulations relating to the design, development, manufacturing, labeling and marketing of our products, and a failure to comply with such regulations could lead to withdrawal or recall of our products from the market.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →